Lipocine reported earnings of -$ 0.08 per LPCN share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.39 |
| Earnings Per Share (Surprise) | -$ 0.08 (+$ 0.31) |
| Last Year's EPS | -$ 0.42 |
| EPS YoY Change |
Out of the last 59 earnings reporting periods, Lipocine beat analysts’ expectations 26 times and fell short of expectations 16 time(s). Lipocine reported earnings per share of -$ 0.08 in the last report surpassing an estimated EPS of -$ 0.39 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.39 | -$ 0.08 | -$ 0.59 | |
| Aug 4, 2026 | -$ 0.40 | -$ 0.32 | -$ 0.41 | |
| May 7, 2026 | -$ 0.51 | -$ 0.54 | -$ 0.35 | |
| Mar 9, 2026 | -$ 0.60 | -$ 0.34 | $ 0.33 | |
| Nov 6, 2025 | -$ 0.56 | -$ 0.59 | -$ 0.44 | |
| Aug 5, 2025 | -$ 0.41 | -$ 0.41 | -$ 0.56 | |
| May 8, 2025 | -$ 0.35 | -$ 0.35 | $ 0.66 | |
| Mar 13, 2025 | -$ 0.40 | $ 0.33 | -$ 0.42 | |
| Nov 7, 2024 | -$ 0.48 | -$ 0.44 | -$ 1.27 | |
| Aug 8, 2024 | -$ 0.78 | -$ 0.56 | -$ 0.68 | |
| May 9, 2024 | -$ 0.68 | $ 0.66 | -$ 0.68 | |
| Mar 7, 2024 | -$ 0.53 | -$ 0.42 | -$ 0.51 | |
| Nov 8, 2023 | -$ 0.57 | -$ 1.27 | -$ 0.51 | |
| Aug 10, 2023 | -$ 0.64 | -$ 0.68 | -$ 0.68 | |
| May 11, 2023 | -$ 0.42 | -$ 0.68 | -$ 0.68 | |
| Mar 10, 2023 | -$ 0.51 | -$ 0.51 | $ 2.55 | |
| Nov 9, 2022 | -$ 0.51 | -$ 0.51 | -$ 0.51 | |
| Aug 8, 2022 | -$ 0.68 | -$ 0.68 | -$ 1.36 | |
| May 9, 2022 | -$ 0.34 | -$ 0.68 | -$ 0.68 | |
| Mar 9, 2022 | -$ 0.85 | $ 2.55 | -$ 1.02 |
Lipocine’s stock was trading at $ 1.44 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, LPCN’s price increased to $ 1.57 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.08 | $ 1.44 | $ 1.57 | |
| Aug 4, 2026 | -$ 0.32 | $ 2.11 | $ 2.17 | |
| May 7, 2026 | -$ 0.54 | $ 2.43 | $ 2.37 | |
| Mar 9, 2026 | -$ 0.34 | $ 8.13 | $ 8.11 | |
| Nov 6, 2025 | -$ 0.59 | $ 2.56 | $ 2.54 | |
| Aug 5, 2025 | -$ 0.41 | $ 3.13 | $ 3.02 | |
| May 8, 2025 | -$ 0.35 | $ 3.30 | $ 3.28 | |
| Mar 13, 2025 | $ 0.33 | $ 3.21 | $ 3.35 | |
| Nov 7, 2024 | -$ 0.44 | $ 6.06 | $ 4.76 | |
| Aug 8, 2024 | -$ 0.56 | $ 5.04 | $ 4.41 | |
| May 9, 2024 | $ 0.66 | $ 4.85 | $ 5.32 | |
| Mar 7, 2024 | -$ 0.42 | $ 3.58 | $ 3.61 | |
| Nov 8, 2023 | -$ 1.27 | $ 2.52 | $ 2.37 | |
| Aug 10, 2023 | -$ 0.68 | $ 5.09 | $ 5.08 | |
| May 11, 2023 | -$ 0.68 | $ 4.52 | $ 4.31 | |
| Mar 10, 2023 | -$ 0.51 | $ 7.14 | $ 6.48 | |
| Nov 9, 2022 | -$ 0.51 | $ 6.65 | $ 6.44 | |
| Aug 8, 2022 | -$ 0.68 | $ 13.99 | $ 12.33 | |
| May 9, 2022 | -$ 0.68 | $ 13.77 | $ 12.92 | |
| Mar 9, 2022 | $ 2.55 | $ 23.97 | $ 25.84 |
Lipocine released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Lipocine beat analysts’ expectations during the last earnings period by
